Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Aimmune Therapeutics, Inc. (AIMT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 10/23/2020 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 10/19/2020 |
8-K
| Quarterly results |
| 10/15/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/15/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/15/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/14/2020 |
4
| Oxtoby Andrew (Chief Commercial Officer) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Unknown transaction of 6,345 shares
@ $34.5, valued at
$218.9k
Disposed/sold 20,250 shares
@ $34.5, valued at
$698.6k
Disposed/sold 150,000 options to buy
@ $21.94, valued at
$3.3M
Disposed/sold 67,500 options to buy
@ $23.81, valued at
$1.6M
|
|
| 10/14/2020 |
4
| Sheehy Douglas T. (See Remarks) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Unknown transaction of 47,450 shares
@ $34.5, valued at
$1.6M
Disposed/sold 36,875 shares
@ $34.5, valued at
$1.3M
Disposed/sold 22,361 options to buy
@ $12.95, valued at
$289.6k
Disposed/sold 67,500 options to buy
@ $19.63, valued at
$1.3M
Disposed/sold 75,000 options to buy
@ $34.07, valued at
$2.6M
Disposed/sold 75,000 options to buy
@ $23.72, valued at
$1.8M
Disposed/sold 67,500 options to buy
@ $23.81, valued at
$1.6M
|
|
| 10/14/2020 |
4
| Dallas Jayson Donald Alexander (President and CEO) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Unknown transaction of 30,422 shares
@ $34.5, valued at
$1M
Disposed/sold 89,250 shares
@ $34.5, valued at
$3.1M
Disposed/sold 350,000 options to buy
@ $30.68, valued at
$10.7M
Disposed/sold 210,000 options to buy
@ $23.72, valued at
$5M
Disposed/sold 200,000 options to buy
@ $23.81, valued at
$4.8M
|
|
| 10/14/2020 |
4
| MCDADE MARK (Director) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Unknown transaction of 26,852 shares
@ $34.5, valued at
$926.4k
Disposed/sold 7,840 shares
@ $34.5, valued at
$270.5k
Disposed/sold 104,842 options to buy
@ $3.02, valued at
$316.6k
Disposed/sold 19,755 options to buy
@ $15.4, valued at
$304.2k
Disposed/sold 17,500 options to buy
@ $18.26, valued at
$319.6k
Disposed/sold 7,500 options to buy
@ $32.79, valued at
$245.9k
Disposed/sold 11,432 options to buy
@ $19.9, valued at
$227.5k
Disposed/sold 15,398 options to buy
@ $17.11, valued at
$263.5k
|
|
| 10/14/2020 |
4
| Behar Gregory (Director) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Disposed of 10,192 shares
@ $0
Disposed/sold 7,840 shares
@ $34.5, valued at
$270.5k
Disposed/sold 39,510 options to buy
@ $24.9, valued at
$983.8k
Disposed/sold 17,500 options to buy
@ $18.26, valued at
$319.6k
Disposed/sold 7,500 options to buy
@ $32.79, valued at
$245.9k
Disposed/sold 11,432 options to buy
@ $19.9, valued at
$227.5k
Disposed/sold 15,398 options to buy
@ $17.11, valued at
$263.5k
|
|
| 10/14/2020 |
4
| HAUMANN BRETT K (Director) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Unknown transaction of 6,250 shares
@ $34.5, valued at
$215.6k
Disposed/sold 13,313 shares
@ $34.5, valued at
$459.3k
Disposed/sold 25,453 options to buy
@ $17.11, valued at
$435.5k
|
|
| 10/14/2020 |
4
| Seltzer Stacey Denenberg (Director) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Unknown transaction of 10,221 shares
@ $34.5, valued at
$352.6k
Disposed/sold 7,840 shares
@ $34.5, valued at
$270.5k
Disposed/sold 52,421 options to buy
@ $6.29, valued at
$329.7k
Disposed/sold 19,755 options to buy
@ $15.4, valued at
$304.2k
Disposed/sold 17,500 options to buy
@ $18.26, valued at
$319.6k
Disposed/sold 7,500 options to buy
@ $32.79, valued at
$245.9k
Disposed/sold 11,432 options to buy
@ $19.9, valued at
$227.5k
Disposed/sold 15,398 options to buy
@ $17.11, valued at
$263.5k
|
|
| 10/14/2020 |
4
| BJERKHOLT ERIC (CFO) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Unknown transaction of 27,805 shares
@ $34.5, valued at
$959.3k
Disposed/sold 23,905 shares
@ $34.5, valued at
$824.7k
Disposed/sold 264,800 options to buy
@ $19.44, valued at
$5.1M
Disposed/sold 56,250 options to buy
@ $34.07, valued at
$1.9M
Disposed/sold 78,750 options to buy
@ $23.72, valued at
$1.9M
Disposed/sold 56,250 options to buy
@ $23.81, valued at
$1.3M
|
|
| 10/14/2020 |
4
| ENRIGHT PATRICK G (Director) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Unknown transaction of 70,561 shares
@ $34.5, valued at
$2.4M
Unknown transaction of 91,697 shares
@ $34.5, valued at
$3.2M
Disposed/sold 7,840 shares
@ $34.5, valued at
$270.5k
Disposed/sold 65,849 options to buy
@ $0.14, valued at
$9.2k
Disposed/sold 52,421 options to buy
@ $6.29, valued at
$329.7k
Disposed/sold 19,755 options to buy
@ $15.4, valued at
$304.2k
Disposed/sold 17,500 options to buy
@ $18.26, valued at
$319.6k
Disposed/sold 7,500 options to buy
@ $32.79, valued at
$245.9k
Disposed/sold 11,432 options to buy
@ $19.9, valued at
$227.5k
Disposed/sold 15,398 options to buy
@ $17.11, valued at
$263.5k
|
|
| 10/14/2020 |
4
| Iwicki Mark T (Director) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Unknown transaction of 39,567 shares
@ $34.5, valued at
$1.4M
Disposed/sold 7,840 shares
@ $34.5, valued at
$270.5k
Disposed/sold 52,421 options to buy
@ $3.02, valued at
$158.3k
Disposed/sold 87,368 options to buy
@ $6.29, valued at
$549.5k
Disposed/sold 19,755 options to buy
@ $15.4, valued at
$304.2k
Disposed/sold 17,500 options to buy
@ $18.26, valued at
$319.6k
Disposed/sold 7,500 options to buy
@ $32.79, valued at
$245.9k
Disposed/sold 11,432 options to buy
@ $19.9, valued at
$227.5k
Disposed/sold 15,398 options to buy
@ $17.11, valued at
$263.5k
|
|
| 10/14/2020 |
4
| ADELMAN DANIEL C MD (Chief Medical Officer) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Unknown transaction of 41,464 shares
@ $34.5, valued at
$1.4M
Disposed/sold 22,343 shares
@ $34.5, valued at
$770.8k
Disposed/sold 135,068 options to buy
@ $11.45, valued at
$1.5M
Disposed/sold 70,000 options to buy
@ $19.63, valued at
$1.4M
Disposed/sold 56,250 options to buy
@ $34.07, valued at
$1.9M
Disposed/sold 71,250 options to buy
@ $23.72, valued at
$1.7M
Disposed/sold 52,500 options to buy
@ $23.81, valued at
$1.3M
|
|
| 10/14/2020 |
4
| FALBERG KATHRYN E (Director) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Unknown transaction of 65,192 shares
@ $34.5, valued at
$2.2M
Unknown transaction of 69,894 shares
@ $34.5, valued at
$2.4M
Disposed/sold 7,840 shares
@ $34.5, valued at
$270.5k
Disposed/sold 19,755 options to buy
@ $15.4, valued at
$304.2k
Disposed/sold 17,500 options to buy
@ $18.26, valued at
$319.6k
Disposed/sold 7,500 options to buy
@ $32.79, valued at
$245.9k
Disposed/sold 11,432 options to buy
@ $19.9, valued at
$227.5k
Disposed/sold 15,398 options to buy
@ $17.11, valued at
$263.5k
|
|
| 10/13/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/13/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/13/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/13/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/13/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 10/13/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/13/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/13/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 10/13/2020 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers: [Amend] |
| 10/13/2020 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 10/13/2020 |
SC 13D/A
| Societe des Produits Nestle S.A. reports a 100% stake in Aimmune Therapeutics, Inc. |
| 10/13/2020 |
SC 13E3/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 10/13/2020 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 10/08/2020 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 10/05/2020 |
4
| ADELMAN DANIEL C MD (Chief Medical Officer) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Exercised 34,932 options to buy
@ $11.45, valued at
$400k
|
|
| 10/05/2020 |
4
| Sheehy Douglas T. (See Remarks) has filed a Form 4 on Aimmune Therapeutics, Inc.|
Txns:
| Exercised 30,888 options to buy
@ $12.95, valued at
$400k
|
|
|
|
|